Targeting epigenetic modifications in Parkinson's disease therapy

Med Res Rev. 2023 Sep;43(5):1748-1777. doi: 10.1002/med.21962. Epub 2023 Apr 29.

Abstract

Parkinson's disease (PD) is a multifactorial disease due to a complex interplay between genetic and epigenetic factors. Recent efforts shed new light on the epigenetic mechanisms involved in regulating pathways related to the development of PD, including DNA methylation, posttranslational modifications of histones, and the presence of microRNA (miRNA or miR). Epigenetic regulators are potential therapeutic targets for neurodegenerative disorders. In the review, we aim to summarize mechanisms of epigenetic regulation in PD, and describe how the DNA methyltransferases, histone deacetylases, and histone acetyltransferases that mediate the key processes of PD are attractive therapeutic targets. We discuss the use of inhibitors and/or activators of these regulators in PD models or patients, and how these small molecule epigenetic modulators elicit neuroprotective effects. Further more, given the importance of miRNAs in PD, their contributions to the underlying mechanisms of PD will be discussed as well, together with miRNA-based therapies.

Keywords: DNA methyltransferase; Parkinson's disease (PD); epigenetics; histone deacetylases; miRNA.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Methylation / genetics
  • Epigenesis, Genetic
  • Histones
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Parkinson Disease* / drug therapy
  • Parkinson Disease* / therapy

Substances

  • Histones
  • MicroRNAs